Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Wilson Therapeutics in connection with its IPO
Mandate

Vinge advised Wilson Therapeutics in connection with its IPO

May 13, 2016

Vinge has advised Wilson Therapeutics AB (publ) in connection with its IPO on Nasdaq Stockholm. The price in the offering was set at SEK 49 per share, corresponding to a
market capitalization of approximately SEK 1,305 million for the total number of outstanding shares in the company (provided that the over-allotment option is utilized).

Vinge’s team primarily consisted of Jesper Ottergren, Erik Sjöman, Christian Lindhé, Ludvig Frithiof, Kristoffer Franzkeit and Astrid Karlsson.

Related

Vinge advises L5 Navigation in connection with the acquisition of Lundaman Instrument

 L5 Navigation Systems AB has acquired the shares in Lundaman Instrument AB. Lundaman develops and supplies weighing systems for wheel loaders and forklift trucks, focusing on the construction, recycling, industrial and materials handling sectors.
May 13, 2026

Vinge advises Aonic in connection with the issuance of subsequent senior secured bonds of EUR 25 million

 Vinge has advised Aonic AB (publ) in connection with the issuance of subsequent senior secured bonds of EUR 25 million, and parallel written procedure to increase the bond framework to EUR 150 million.
May 12, 2026

Vinge advises Consolid Equity and other sellers on the sale of Sertion to Altor

 Vinge has advised Consolid Equity and other sellers on the sale of the Sertion Group to Altor. In connection with the transaction, entrepreneurs and management will reinvest and remain as key owners, partnering with Altor to accelerate the group’s next phase of growth across existing markets and into new geographies.
May 11, 2026